Effect of Folic Acid therapy on Homocysteine Level in patients with Atherosclerosis or Buerger's Disease and in Healthy individuals: A Nonrandomized clinical trial study

Phase 1

• Conditions: buerger diseasehyperhomocysteinemiavascular occlusions; Buerger’s disease; atherosclerosis; homocysteine; folic acid

• Registration Number: TCTR20160601003
• Lead Sponsor: none

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2011-02-04
• Study Start: 2016-06-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Enrolling by invitation
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

buerger disease patients have Shionoya criteria and atherosclerosis was proved by angiography

Exclusion Criteria

The exclusion criteria were age under 18 years; alcohol consumption; recent use of methotrexate, trimethoprim, phenytoin, carbamazepine, or theophylline; and underlying diseases such as malignancy, systemic diseases, systemic lupus erythematosus, rheumatoid arthritis, and hypothyroidism. To minimize the possible interactions of confounding factors, vitamin B12, 1000 U/w, was intravenously administered to all of the participants one week prior to the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
homocysteine 04/02/2011 Axis® Homocysteine Enzyme Immunoassay (EIA) kit (UK).

Secondary Outcome Measures

Name	Time	Method
homocysteine 04/02/2011 Axis® Homocysteine Enzyme Immunoassay (EIA) kit (UK).